Subcutaneous Furosemide**

A Major Advance in Heart Failure Treatment

Furosemide, the treatment of choice for fluid overload in heart failure, has previously only been available in oral and intravenous (IV) forms. For patients for whom oral medication was insufficient, IV administration in a clinical setting was the only choice.

Now, scPharmaceuticals is making furosemide available for the first time for subcutaneous use, dispensed with its sc2Wear™ Infusor.

The company’s proprietary furosemide formulation has been optimized for use with the sc2Wear™ Infusor. Its pH has been reduced to a neutral level to minimize the risk of local irritation or discomfort.

UPDATE: On November 4, 2015, the company announced the pivotal trial results of its proprietary subcutaneous furosemide formulation in patients with heart failure. The results indicated that the subcutaneous administration of the novel furosemide formulation was as effective as the traditional intravenous administration in getting furosemide into the blood stream, and in achieving diuresis. Please click here to read the full release.

scPharmaceuticals’ furosemide formulation Furosemide injection, USP
Administration Subcutaneous Administration – 80mg by biphasic delivery Intravenous Administration – 2x 40mg IV at t0 and t2h
Bioavailability (t:0-24h) 100%* 100%
Diuresis 0-8 hours 2,654 mL 2,610 mL
Diuresis 0-24 hours 3,630 mL 3, 538 mL

Potential Benefits of Furosemide for Subcutaneous Delivery:

  • Greater flexibility as to where and by whom furosemide can be administered
  • Avoidance of need for IV placement
  • Reduced cost of care

Enhance Patient Care in a Wide Range of Situations

  • Reverse a Course of Deterioration: When oral alone is insufficient, subcutaneous furosemide may help to reverse worsening heart failure and prevent an ER visit or hospitalization.
  • Send a Patient Home Earlier: Diuresis takes time – the average patient loses more than 15 pounds during a standard 5-6 day hospital stay.   Some patients may be sent home several days earlier with use of subcutaneous furosemide.
  • Treat after Discharge: Research suggests that many patients despite feeling better still have considerable fluid overload upon discharge.   Some patients may benefit from additional days of outpatient or home treatment to achieve their treatment target and reduce the risk of readmission.
  • Increase Patient Comfort: Vascular access (placing an IV) may be difficult, time consuming and painful for some patients. Subcutaneous administration eliminates the need for IV. This may be of particular importance in end-of-life / hospice care situations.
  • Augment a Chronic Care Regimen: For some patients, oral furosemide alone is in not enough. These patients slowly retain water and salt and subcutaneous furosemide may help prevent further fluid build-up.

New Options for Clinics, Nursing Homes, Hospice, and Home Health

Furosemide for Subcutaneous Delivery has applications in a broad range of settings.

Case Study 1: Avoiding the ER/Diuresis Clinic

Traditional Paradigm: A patient has increasing heart failure symptoms over a 10-day interval from increased fluid retention. An increase in oral furosemide fails to resolve the symptoms. The physician directs the patient to the ER for intravenous furosemide. The patient returns home after about 12 hours feeling better. Although successful, the patient discomfort and burden to the family is considerable.

New Paradigm: Instead of sending the patient to the ER, the physician prescribes furosemide for subcutaneous delivery with the sc2Wear™ Infusor, which is prepared and placed by the nurse.   The patient activates the sc2Wear™ Infusor at home and experiences marked diuresis in the comfort of his home. The expense and burden of an ER visit are avoided.

Patient Journey without cost elements


Case Study 2: Reducing the Length of Stay

Traditional Paradigm: A patient is admitted to the hospital for treatment of fluid overload. After 5 days in the hospital and the loss of approximately 2 gallons of fluid, she is discharged home with some residual excess fluid. The cost of the hospital stay exceeds $16,000. After returning home her symptoms quickly return and within 30 days, she needs to be readmitted.   Approximately 25% of heart failure patients are readmitted within 30 days after a standard in-patient stay of 5-6 days.

New Paradigm: A patient is admitted to the hospital for treatment of fluid overload. After two days, she is given a successful test treatment with the sc2Wear™ Infusor during which she is also trained on its use. She is discharged with dosing for five more additional days. She communicates daily with her healthcare provider. After two days she visits her physician for a check-up, including checking of electrolytes. After three more days and another check-up, she has completed treatment in the comfort of her home.


**CAUTION: Investigational Product – Limited by Federal Law to Investigational Use.